The University of Chicago Header Logo

Connection

Arlene Chapman to Hypertension

Back to Details
This is a "connection" page, showing publications Arlene Chapman has written about Hypertension.
Arlene Chapman
Connection Strength
6.598
Hypertension
  1. Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. PLoS One. 2019; 14(9):e0221957.
    View in: PubMed
    Score: 0.383
  2. The future of pharmacogenetics in the treatment of hypertension. Pharmacogenomics. 2019 02; 20(3):129-132.
    View in: PubMed
    Score: 0.368
  3. Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/ß-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials. J Am Heart Assoc. 2017 Nov 02; 6(11).
    View in: PubMed
    Score: 0.336
  4. A Physiologic Approach to the Pharmacogenomics of Hypertension. Adv Chronic Kidney Dis. 2016 Mar; 23(2):91-105.
    View in: PubMed
    Score: 0.299
  5. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014 Dec; 29(12):2194-201.
    View in: PubMed
    Score: 0.259
  6. Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension. Am J Hypertens. 2014 Apr; 27(4):546-54.
    View in: PubMed
    Score: 0.250
  7. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol. 2010 Jan; 5(1):102-9.
    View in: PubMed
    Score: 0.195
  8. Renal volume in children with ADPKD: size matters. Clin J Am Soc Nephrol. 2009 Apr; 4(4):698-9.
    View in: PubMed
    Score: 0.185
  9. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008 Jan; 21(1):61-6.
    View in: PubMed
    Score: 0.170
  10. Circulating microRNA Biomarkers of Thiazide Response in Hypertension. J Am Heart Assoc. 2024 Feb 20; 13(4):e032433.
    View in: PubMed
    Score: 0.130
  11. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int. 2002 Mar; 61(3):1047-55.
    View in: PubMed
    Score: 0.113
  12. Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. Kidney360. 2022 02; 3(2):307-316.
    View in: PubMed
    Score: 0.113
  13. Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone. Am J Med. 2021 07; 134(7):918-925.e2.
    View in: PubMed
    Score: 0.105
  14. Sorting nexin 1 loss results in increased oxidative stress and hypertension. FASEB J. 2020 06; 34(6):7941-7957.
    View in: PubMed
    Score: 0.100
  15. Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence. Am J Hypertens. 2020 02 22; 33(2):e2.
    View in: PubMed
    Score: 0.099
  16. Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response. Sci Rep. 2019 11 21; 9(1):17323.
    View in: PubMed
    Score: 0.097
  17. Genome-Wide Meta-Analysis of Blood Pressure Response to ß1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). J Am Heart Assoc. 2019 08 20; 8(16):e013115.
    View in: PubMed
    Score: 0.095
  18. Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy. Pharmacogenet Genomics. 2019 01; 29(1):18-22.
    View in: PubMed
    Score: 0.091
  19. Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide. Pharmacogenet Genomics. 2018 11; 28(11):251-255.
    View in: PubMed
    Score: 0.090
  20. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dial Transplant. 2018 04 01; 33(4):645-652.
    View in: PubMed
    Score: 0.086
  21. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circ Genom Precis Med. 2018 04; 11(4):e001854.
    View in: PubMed
    Score: 0.086
  22. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade? Curr Hypertens Rev. 2018; 14(1):39-47.
    View in: PubMed
    Score: 0.085
  23. Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. J Am Heart Assoc. 2017 12 29; 7(1).
    View in: PubMed
    Score: 0.085
  24. Autosomal dominant polycystic kidney disease. CMAJ. 2017 11 13; 189(45):E1396.
    View in: PubMed
    Score: 0.084
  25. Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension. J Clin Hypertens (Greenwich). 2017 Dec; 19(12):1301-1308.
    View in: PubMed
    Score: 0.083
  26. Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response. Circ Cardiovasc Genet. 2017 Jan; 10(1).
    View in: PubMed
    Score: 0.079
  27. Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide. Hypertension. 2017 01; 69(1):51-59.
    View in: PubMed
    Score: 0.078
  28. A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. Hypertension. 2016 09; 68(3):621-9.
    View in: PubMed
    Score: 0.077
  29. Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension. Am J Hypertens. 2016 10; 29(10):1186-94.
    View in: PubMed
    Score: 0.077
  30. Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to ß-Blockers in Hypertensive African Americans. Hypertension. 2016 Mar; 67(3):556-63.
    View in: PubMed
    Score: 0.074
  31. PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. J Hypertens. 2015 Nov; 33(11):2278-85.
    View in: PubMed
    Score: 0.073
  32. TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens. 2015 Jun; 33(6):1301-9.
    View in: PubMed
    Score: 0.071
  33. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015 Jul; 88(1):17-27.
    View in: PubMed
    Score: 0.070
  34. Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients. Metab Syndr Relat Disord. 2015 Jun; 13(5):195-202.
    View in: PubMed
    Score: 0.070
  35. Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc. 2015 Jan 26; 4(1):e001521.
    View in: PubMed
    Score: 0.069
  36. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2267-76.
    View in: PubMed
    Score: 0.068
  37. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2255-66.
    View in: PubMed
    Score: 0.068
  38. Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension. J Am Heart Assoc. 2014 Nov 10; 3(6):e001398.
    View in: PubMed
    Score: 0.068
  39. Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. Pharmacotherapy. 2014 Nov; 34(11):1132-40.
    View in: PubMed
    Score: 0.068
  40. Is diabetes mellitus-linked amino acid signature associated with ß-blocker-induced impaired fasting glucose? Circ Cardiovasc Genet. 2014 Apr; 7(2):199-205.
    View in: PubMed
    Score: 0.065
  41. Baseline predictors of central aortic blood pressure: a PEAR substudy. J Am Soc Hypertens. 2014 Mar; 8(3):152-8.
    View in: PubMed
    Score: 0.064
  42. PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment. Pharmacotherapy. 2014 Feb; 34(2):123-30.
    View in: PubMed
    Score: 0.063
  43. Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. PLoS One. 2013; 8(10):e76984.
    View in: PubMed
    Score: 0.063
  44. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension. 2013 Aug; 62(2):391-7.
    View in: PubMed
    Score: 0.062
  45. The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension. Am J Hypertens. 2013 Aug; 26(8):957-64.
    View in: PubMed
    Score: 0.061
  46. Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens. 2013 Apr; 31(4):698-704.
    View in: PubMed
    Score: 0.061
  47. Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One. 2013; 8(3):e57639.
    View in: PubMed
    Score: 0.061
  48. Impact of genetic polymorphisms of SLC2A2, SLC2A5, and KHK on metabolic phenotypes in hypertensive individuals. PLoS One. 2013; 8(1):e52062.
    View in: PubMed
    Score: 0.060
  49. Response to genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension. 2013 Jan; 61(1):e6.
    View in: PubMed
    Score: 0.060
  50. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet. 2012 Dec; 5(6):686-91.
    View in: PubMed
    Score: 0.059
  51. G protein receptor kinase 4 polymorphisms: ß-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension. 2012 Oct; 60(4):957-64.
    View in: PubMed
    Score: 0.059
  52. Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. Kidney Blood Press Res. 2012; 35(6):477-82.
    View in: PubMed
    Score: 0.058
  53. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension. 2012 Jun; 59(6):1204-11.
    View in: PubMed
    Score: 0.057
  54. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012 Mar; 81(6):577-85.
    View in: PubMed
    Score: 0.056
  55. Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. Am J Hypertens. 2012 Mar; 25(3):359-65.
    View in: PubMed
    Score: 0.056
  56. Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011 Oct; 6(10):2508-15.
    View in: PubMed
    Score: 0.055
  57. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics. 2011 Jan; 21(1):42-9.
    View in: PubMed
    Score: 0.052
  58. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens. 2010 Sep; 23(9):1014-22.
    View in: PubMed
    Score: 0.051
  59. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010 Jan; 55(1):61-8.
    View in: PubMed
    Score: 0.048
  60. Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Pharmacotherapy. 2009 Oct; 29(10):1157-65.
    View in: PubMed
    Score: 0.048
  61. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension. 2008 Aug; 52(2):359-65.
    View in: PubMed
    Score: 0.044
  62. WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension. 2005 Oct; 46(4):758-65.
    View in: PubMed
    Score: 0.036
  63. Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens. 2005 Aug; 18(8):1077-83.
    View in: PubMed
    Score: 0.036
  64. Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. Am J Hypertens. 2005 Mar; 18(3):398-402.
    View in: PubMed
    Score: 0.035
  65. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens. 2003 Oct; 16(10):834-9.
    View in: PubMed
    Score: 0.032
  66. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2003 Sep; 64(3):1035-45.
    View in: PubMed
    Score: 0.031
  67. Reproducibility of blood pressure response to hydrochlorothiazide. J Clin Hypertens (Greenwich). 2002 Nov-Dec; 4(6):408-12.
    View in: PubMed
    Score: 0.030
  68. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002 Jul; 13(7):1733-9.
    View in: PubMed
    Score: 0.029
  69. ß2 -Adrenergic Receptor Gene Affects the Heart Rate Response of ß-Blockers: Evidence From 3 Clinical Studies. J Clin Pharmacol. 2019 11; 59(11):1462-1470.
    View in: PubMed
    Score: 0.023
  70. Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies. Eur J Pharm Sci. 2019 Apr 01; 131:93-98.
    View in: PubMed
    Score: 0.023
  71. Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. BMC Med Genomics. 2018 Jun 20; 11(1):55.
    View in: PubMed
    Score: 0.022
  72. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol. 2016 05 06; 11(5):803-811.
    View in: PubMed
    Score: 0.019
  73. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int. 2003 Dec; 64(6):2214-21.
    View in: PubMed
    Score: 0.008
  74. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem. 2002 Nov; 48(11):1919-23.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.